Subhasree Rajaram
YOU?
Author Swipe
View article: Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer
Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer Open
New treatments are urgently required for triple-negative breast cancer (TNBC). As TP53 is mutated in approximately 80% of TNBC, it is theoretically an attractive target for new drugs for this disease. Arsenic trioxide (ATO), which is used …
View article: Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? Open
Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug, several new strategies have recently become available for targeting the mutant protein. One of the most promi…